XL184 (cabozantinib) for medullary thyroid carcinoma

Bibliography

• Kloos RT, Eng C, Evans DB, Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612
   PubMed Web of Science ®Google Scholar
• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7
   PubMed Web of Science ®Google Scholar
• Chiefari E, Russo D, Giuffrida D, Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. J Endocrinol Invest 1998;21:358-64
   PubMed Web of Science ®Google Scholar
• Santoro M, Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2006;2:42-52
   PubMedGoogle Scholar
• Castellone MD, Verrienti A, Rao DM, A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clin Endocrinol (Oxf) 2010;73:529-34
   PubMed Web of Science ®Google Scholar
• Santoro M, Carlomagno F, Melillo RM, Molecular mechanisms of RET activation in human neoplasia. J Endocrinol Invest 1999;22:811-19
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Baudin E, Travagli JP, Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004;61:299-310
   PubMed Web of Science ®Google Scholar
• Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42
   PubMed Web of Science ®Google Scholar
• Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol 2010;322:2-7
   PubMed Web of Science ®Google Scholar
• Vitale G, Caraglia M, Ciccarelli A, Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001;91:1797-808
   PubMed Web of Science ®Google Scholar
• Sugawara M, Geffner DL, Martinez D, Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes 2009;16:367-72
   PubMed Web of Science ®Google Scholar
• Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol 2010;80:592-601
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen LS, Vokes EE, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49
   PubMed Web of Science ®Google Scholar
• de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:3466-9
   PubMed Web of Science ®Google Scholar
• Schlumberger MJ, Elisei R, Bastholt L, Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801
   PubMed Web of Science ®Google Scholar
• Lam ET, Ringel MD, Kloos RT, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30
   PubMed Web of Science ®Google Scholar
• De Souza JA, Busaidy N, Zimrin A, Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol 2010;28(7S): abstract 5504
   Google Scholar
• Vandetanib (ZD6474) tablets Oncologic Drugs Advisory Committee (ODAC) meeting briefing document. FDA Public Health Advisory. Washington, DC: FDA/ Oncologic Drugs Advisory Committee, 2010. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM235092.pdf [Last accessed 24 January 2011]
   Google Scholar
• Wells SA Jr, Gosnell JE, Gagel RF, Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72
   PubMed Web of Science ®Google Scholar
• Wells SA, Robinson BG, Gagel RF, Vandetanib in locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial (ZETA). J Clin Oncol 2010;28(15S): abstract 5503
   Google Scholar
• Papotti M, Olivero M, Volante M, Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 2000;11:19-30
   PubMed Web of Science ®Google Scholar
• Pennacchietti S, Michieli P, Galluzzo M, Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61
   PubMed Web of Science ®Google Scholar
• Bardelli A, Basile ML, Audero E, Concomitant activation of pathways downstream of Grb2 and PI3-kinase is required for MET-mediated metastasis. Oncogene 1999;18:1139-46
   PubMed Web of Science ®Google Scholar
• Zhang YW, Su Y, Volpert OV, Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003;100:12718-23
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Cohen EE, Sherman SI, Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. J Clin Oncol 2010;28(15S): abstract 5502
   Google Scholar
• Salgia R, Hong D, Sherman SI, A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. Mol Cancer Ther 2007;19: abstract A152
   Google Scholar
• Salgia R, Hong DS, Camacho LH, A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2007;25(18S): abstract 14031
   Google Scholar
• Salgia R, Sherman S, Hong DS, Phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 2008;26(15S): abstract 3522
   PubMedGoogle Scholar
• Kurzrock R, Sherman S, Hong D, A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) [abstract 379]. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Theurapeutics; Geneva; 2008
   Google Scholar
• Zhang Y, Guessous F, Kofman A, XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010;13:112-21
   PubMed Web of Science ®Google Scholar
• Murakami H, Yamamura Y, Shimono Y, Role of Dok1 in cell signaling mediated by RET tyrosine kinase. J Biol Chem 2002;277:32781-90
   PubMed Web of Science ®Google Scholar
• De Groot JW, Links TP, Plukker JT, RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006;27:535-60
   PubMed Web of Science ®Google Scholar
• Plaza-Menacho I, Burzynski G, de Groot JW, Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet 2006;22:627-36
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Guida T, Anaganti S, Disease associated mutations at valine the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004;23:6056-63
   PubMed Web of Science ®Google Scholar
• Stommel JM, Kimmelman AC, Ying H, Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90
   PubMed Web of Science ®Google Scholar
• Johnston JB, Navaratnam S, Pitz MW, Targeting the EGFR pathway for cancer therapy. Curr Med Chem 2006;13:3483-92
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
   PubMed Web of Science ®Google Scholar
• Sennino B, Naylor RM, Tabruyn SP, Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-TAG2 mice after inhibition of VEGFR plus C-MET by XL 184. Mol Cancer Ther 2009;8: abstract 13
   Google Scholar
• Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48
   PubMed Web of Science ®Google Scholar